RT期刊文章SR电子T1标准化较短的方案相对个性化的利福平或多药抗性结核方案JF欧洲呼吸杂志Jo EUR RESPIR J FD欧洲呼吸学会SP 1901467 DO 10.1183 / 13993003.01467-2019 VO 55是3 A1 Abidi，Syed A1 Achar，Jay A1 As188bet官网地址sao Neino，Mourtala Mohamed A1Bang，Didi A1 Benedetti，Andrea A1 Bode，Sarah A1 Campbell，Jonathon R. A1 Casas，Esther C. A1 Conradie，Francesca A1 Dravniece，Philipl A1 Dravniece，Philipp A1 Falzon，Dennis A1 Jaramillo，Ernesto A1 Kuaban，Christopher A1 Lan，Christopher A1 Lan，智商A1 Lange，Christoph A1，Pei Zhi A1 Makhmudova，Mavluda A1 Maug，Aung Kya Jai A1 Menzies，Dick A1 Migliori，Giovanni Battista A1 Miller，Ann A1 Myrzaliev，Bakyt A1 Ndjeka，Norbert A1 Noeske，JürgenA1Parpieva，NargizaA1 Piubello，阿尔贝托A1 Schwoebel势，瓦莱丽A1 Sikhondze，Welile A1 Singla，Rupak A1苏莱曼，穆罕默杜·巴西鲁A1Trébucq，阿尔诺A1范Deun，阿尔芒A1维妮，凯丽A1韦耶，卡琳A1张，贝蒂张敬轩A1·艾哈迈德·汗，法伊兹YR 2020ul http://erj.ersjournals.co.M / Content / 55/3 / 1901467.我们试图比较两个世界卫生组织（世卫组织）的效力 - 用于治疗利福平或多药物抗性（RR / MDR）结核（TB）的疗效：a标准化方案为9-12个月（“较短的方案”）和≥20个月的个性化方案（“更长的方案”）。我们从通过系统审查和公共呼吁确定的观察研究中收集了个别患者数据。我们包括符合较短方案的资格标准的患者：之前未用二线药物治疗，并用氟代喹啉和二线可注射剂 - 易感RR / MDR-TB治疗。我们使用倾向评分匹配，混合效应元回归，计算调整后的差异比例和调整后的风险差异（ARDS）进行失败或复发，治疗后12个月内的死亡和后续行动的死亡。3378中包括2625次（77.7％）从53项较长方案的研究中的较短方案和13个104（20.7％）个体中的九个研究的个体。治疗成功较短，方案较短，比较较长的方案（汇总比例80.0％而75.3％），由于前者的随访较少（ARD -0.15,95％CI -0.17-0.12）。 The risk difference for failure or relapse was slightly higher with the shorter regimen overall (aRD 0.02, 95% CI 0–0.05) and greater in magnitude with baseline resistance to pyrazinamide (aRD 0.12, 95% CI 0.07–0.16), prothionamide/ethionamide (aRD 0.07, 95% CI −0.01–0.16) or ethambutol (aRD 0.09, 95% CI 0.04–0.13).In patients meeting WHO criteria for its use, the standardised shorter regimen was associated with substantially less loss to follow-up during treatment compared with individualised longer regimens and with more failure or relapse in the presence of resistance to component medications. Our findings support the need to improve access to reliable drug susceptibility testing.Standardised shorter regimens for RR/MDR-TB had substantially lower risk of loss to follow-up than individualised longer regimens, but also higher risk of failure or relapse if there was resistance to component drugs http://bit.ly/2RQgXzq